Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study

Raymond S.M. Wong, Mansoor N. Saleh, Abderrahim Khelif, Abdulgabar Salama, Maria Socorro O. Portella, Paul Burgess and James B. Bussel
This article has an Erratum 131(6):709

Article Information


Print ISSN 
Online ISSN 
  • Submitted April 6, 2017
  • Accepted October 4, 2017
  • Published online October 17, 2017.

Article Versions

  • Raymond S.M. Wong, 1 Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, NT, Hong Kong;
  • Mansoor N. Saleh, 2 Hematology & Oncology, The University of Alabama at Birmingham, Birmingham, AL, United States;
  • Abderrahim Khelif, 3 Hematology Department, Hopital Farhat Hached, Sousse, Tunisia;
  • Abdulgabar Salama, 4 Institute for Transfusion Medicine, Charite-Universitaetsmedizin Berlin, Berlin, Germany;
  • Maria Socorro O. Portella, 5 Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States;
  • Paul Burgess, 6 Oncology Global Development, Novartis Pharma, AG, Basel, Switzerland;
  • James B. Bussel, 7 Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY, United States Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output